Seven solutions for neuroprotection in Parkinson’s disease - Archive ouverte HAL Access content directly
Journal Articles Movement Disorders Year : 2020

Seven solutions for neuroprotection in Parkinson’s disease

(1) , (2) , (3)
1
2
3

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra, and accumulation of iron and alpha-synuclein; it follows a characteristic pattern throughout the nervous system. Despite, decades of successful preclinical neuroprotective studies, no drug has then shown efficacy in clinical trials. Considering this dilemma, we have reviewed and organized solutions of different (varying – might be a better word) importance that can be exclusive or additive and outline approaches to help generate successful development of neuroprotective drugs for PD: 1) select patients in which the targeted mechanism is involved in the pathological process associated with the monitoring of target engagement; 2) combine treatments that target multiple pathways; 3) establish earliest interventions and develop better prodromal biomarkers; 4) adopt rigorous methodology and specific disease-relevant designs for disease-modifying clinical trials; 5) customize drug with better brain biodistribution; 6) prioritize repurposed drugs as a first line approach; 7) adapt preclinical models to the targeted mechanisms with translational biomarkers to increase their predictive value.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-02994649 , version 1 (08-11-2020)

Identifiers

  • HAL Id : inserm-02994649 , version 1

Cite

David Devos, Etienne Hirsch, Richard Wyse. Seven solutions for neuroprotection in Parkinson’s disease. Movement Disorders, In press. ⟨inserm-02994649⟩
95 View
1 Download

Share

Gmail Facebook Twitter LinkedIn More